How to buy Stealth BioTherapeutics shares | $1.53

Own Stealth BioTherapeutics shares in just a few minutes. Share price changes are updated daily.

Stealth BioTherapeutics Corp (MITO) is a leading biotechnology business based in the US. In the week up to 6 June Stealth BioTherapeutics shares surged 26.28% to a closing position of $1.73. However, over the last 12 months, Stealth BioTherapeutics's share price has fallen by 22.34% from $1.97. Stealth BioTherapeutics is listed on the NASDAQ and employs 29 staff. All prices are listed in US Dollars.

How has coronavirus impacted Stealth BioTherapeutics's share price?

Since the stock market crash that started in February 2020, Stealth BioTherapeutics's share price has had significant negative movement.

Its last market close was $1.37, which is 35.98% down on its pre-crash value of $2.14 and 52.19% up on the lowest point reached during the March 2020 crash when the shares fell as low as $0.9002.

If you had bought $1,000 worth of Stealth BioTherapeutics shares at the start of February 2020, those shares would have been worth $440.04 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $548.00.

Stealth BioTherapeutics share price

Use our graph to track the performance of MITO stocks over time.

Stealth BioTherapeutics shares at a glance

Information last updated 2021-06-18.
Open$1.55
High$1.57
Low$1.5
Close$1.53
Previous close$1.52
Change $0.01
Change % 0.6579%
Volume 299,395
Information last updated 2021-06-17.
52-week range$1.06 - $2.5
50-day moving average $1.4117
200-day moving average $1.5379
Wall St. target price$3.33
Dividend yield N/A (0%)
Earnings per share (TTM) $-6.674
Promoted
eToro Free Stocks

Invest in Stealth BioTherapeutics shares with 0% commission

Other fees apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • Pay no stamp duty on UK shares (saving 0.5%)
  • Create an account today in a few minutes

Share dealing platform comparison

Table: sorted by promoted deals first
Name Product Ratings Finder rating Customer rating Min. initial deposit Price per trade Frequent trader rate Platform fee Offer Link
Hargreaves Lansdown Fund and Share Account
Finder score
★★★★★
User survey
★★★★★
★★★★★
Expert analysis
★★★★★
User survey
£1
£11.95
£5.95
£0

Capital at risk

Platform details
FREE TRADES
eToro Free Stocks
Finder score
★★★★★
User survey
★★★★★
★★★★★
Expert analysis
★★★★★
User survey
$200
£0
N/A
£0

Capital at risk

Platform details
FREE TRADES
Stake
Finder score
★★★★★
User survey
★★★★★
★★★★★
Expert analysis
★★★★★
User survey
£50
US: £0
N/A
£0
Join and receive a free share worth up to £100

Capital at risk

Platform details
Degiro Share Dealing
Finder score
★★★★★
★★★★★
Expert analysis
Not yet rated
£0.01
UK: £1.75 + 0.014% (max £5)
US: €0.50 + $0.004 per share
N/A
£0

Capital at risk

Platform details
interactive investor Trading Account
Finder score
★★★★★
User survey
★★★★★
★★★★★
Expert analysis
★★★★★
User survey
£0
£7.99 (with one free trade per month)
N/A
£9.99 per month

Capital at risk

Platform details
loading

Compare up to 4 providers

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is it a good time to buy Stealth BioTherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Stealth BioTherapeutics price performance over time

Historical closes compared with the last close of $1.53

1 week (2021-06-11) -4.38%
1 month (2021-05-19) 15.04%
3 months (2021-03-19) -22.73%
6 months (2020-12-18) 4.08%
1 year (2020-06-19) -22.34%
2 years (2019-06-19) -88.00%

Financials

Revenue TTM $21.1 million
Gross profit TTM $21.1 million
Return on assets TTM -83.53%
Return on equity TTM -1666.63%
Profit margin 0%
Book value $0.046
Market capitalisation $84.5 million

TTM: trailing 12 months

How to short and sell Stealth BioTherapeutics shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "MITO.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 789,092 Stealth BioTherapeutics shares held short by investors – that's known as the "short interest". This figure is 49.5% down from 1.6 million last month.

There are a few different ways that this level of interest in shorting Stealth BioTherapeutics shares can be evaluated.

Short interest ratio (SIR)

Stealth BioTherapeutics's "short interest ratio" (SIR) is the quantity of Stealth BioTherapeutics shares currently shorted divided by the average quantity of Stealth BioTherapeutics shares traded daily (recently around 11.3 million). Stealth BioTherapeutics's SIR currently stands at 0.07. In other words for every 100,000 Stealth BioTherapeutics shares traded daily on the market, roughly 70 shares are currently held short.

However Stealth BioTherapeutics's short interest can also be evaluated against the total number of Stealth BioTherapeutics shares, or, against the total number of tradable Stealth BioTherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Stealth BioTherapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Stealth BioTherapeutics shares in existence, roughly 10 shares are currently held short) or 0.0428% of the tradable shares (for every 100,000 tradable Stealth BioTherapeutics shares, roughly 43 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Stealth BioTherapeutics.

Find out more about how you can short Stealth BioTherapeutics stock.

Stealth BioTherapeutics share dividends

We're not expecting Stealth BioTherapeutics to pay a dividend over the next 12 months. Typically it's companies that have been around for longer that pay dividends (Stealth BioTherapeutics had its IPO on 15 February 2019). However, you can browse other dividend-paying shares in our guide.

Share price volatility

Over the last 12 months, Stealth BioTherapeutics's shares have ranged in value from as little as $1.06 up to $2.5. A popular way to gauge a stock's volatility is its "beta".

MITO.US volatility(beta: 2.02)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Stealth BioTherapeutics's is 2.0205. This would suggest that Stealth BioTherapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Win £500 to get your trading started

Subscribe to trending stock alerts for a chance to win

By submitting, you agree to the Finder Privacy and Cookies Policy and Terms of Use

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked
Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site